caffeine has been researched along with Alzheimer Disease in 127 studies
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| " In particular, several cross-sectional and longitudinal population-based studies suggested a protective effect of coffee, tea, and caffeine use against late-life cognitive impairment/decline, although the association was not found in all cognitive domains investigated and there was a lack of a distinct dose-response association, with a stronger effect among women than men." | 6.52 | Coffee, tea, and caffeine consumption and prevention of late-life cognitive decline and dementia: a systematic review. ( Barulli, MR; Bonfiglio, C; Guerra, V; Logroscino, G; Osella, A; Panza, F; Pilotto, A; Sabbà, C; Seripa, D; Solfrizzi, V, 2015) |
| "Cilostazol (CSZ) has been shown to be a new treatment for cognitive impairment with limited efficacy." | 5.72 | Advancing combination treatment with cilostazol and caffeine for Alzheimer's disease in high fat-high fructose-STZ induced model of amnesia. ( Ahmed, AM; El-Mokhtar, MA; Farghaly, HSM; Gomaa, AA; Hemida, FK, 2022) |
| "Dementia and Alzheimer's disease (AD) are rapidly increasing public health problems in ageing populations and at the moment curative treatment is lacking." | 5.36 | Caffeine as a protective factor in dementia and Alzheimer's disease. ( Eskelinen, MH; Kivipelto, M, 2010) |
| "We report that performance on neuropsychological tests used in the diagnosis of dementia can be influenced by external factors such as time of day (TOD) and caffeine." | 5.20 | Time of day and caffeine influence some neuropsychological tests in the elderly. ( Lesk, VE; Walters, ER, 2015) |
| " The pooled odds ratio (OR) or relative risk (RR) of caffeine intake from coffee or tea for cognitive disorders (dementia, Alzheimer's disease, cognitive impairment, and cognitive decline) was 0." | 4.91 | Caffeine intake from coffee or tea and cognitive disorders: a meta-analysis of observational studies. ( Kim, YS; Kwak, SM; Myung, SK, 2015) |
| " Here we have analyzed naturally occurring MTXs caffeine, theobromine, theophylline, and the synthetic MTXs pentoxifylline and propentofylline also used as drugs in different neuroblastoma cell lines." | 4.12 | Methylxanthines Induce a Change in the AD/Neurodegeneration-Linked Lipid Profile in Neuroblastoma Cells. ( Bachmann, CM; Griebsch, LV; Grimm, HS; Grimm, MOW; Hartmann, T; Janitschke, D; Lauer, AA; Pilz, SM; Theiss, EL; Winkler, J, 2022) |
| "The increasing numbers of elderly Alzheimer's disease (AD) patients because of a steady increase in the average lifespan and aging society attract great scientific concerns, while there were fewer effective treatments on AD progression due to unclear exact causes and pathogenesis of AD." | 2.72 | The Neuroprotective Effects of Moderate and Regular Caffeine Consumption in Alzheimer's Disease. ( Zhang, L; Zhou, X, 2021) |
| " In particular, several cross-sectional and longitudinal population-based studies suggested a protective effect of coffee, tea, and caffeine use against late-life cognitive impairment/decline, although the association was not found in all cognitive domains investigated and there was a lack of a distinct dose-response association, with a stronger effect among women than men." | 2.52 | Coffee, tea, and caffeine consumption and prevention of late-life cognitive decline and dementia: a systematic review. ( Barulli, MR; Bonfiglio, C; Guerra, V; Logroscino, G; Osella, A; Panza, F; Pilotto, A; Sabbà, C; Seripa, D; Solfrizzi, V, 2015) |
| "AD (Alzheimer's disease) is the most prevalent form of dementia in the aged population." | 2.50 | From epidemiology to pathophysiology: what about caffeine in Alzheimer's disease? ( Batalha, VL; Blum, D; Boison, D; Buée, L; Burnouf, S; Coelho, JE; Flaten, V; Hamdane, M; Humez, S; Laurent, C; Lopes, LV; Sandau, U, 2014) |
| " While coffee and caffeine are known to enhance short-term memory and cognition, some limited research also suggests that long-term use may protect against cognitive decline or dementia." | 2.50 | Current evidence for the use of coffee and caffeine to prevent age-related cognitive decline and Alzheimer's disease. ( Carman, AJ; Dacks, PA; Fillit, HM; Lane, RF; Shineman, DW, 2014) |
| "Neurodegenerative disorders are some of the most feared illnesses in modern society, with no effective treatments to slow or halt this neurodegeneration." | 2.47 | Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies. ( Chen, JF; Chern, Y, 2011) |
| "Caffeine is a widely consumed psychoactive drug, which is emerging as a protective agent against AD progression and in aging associated deficits." | 2.47 | Modulating Alzheimer's disease through caffeine: a putative link to epigenetics. ( Batalha, VL; Lopes, LV; Marques, S; Outeiro, TF, 2011) |
| "Sporadic Alzheimer's disease (AD) and Parkinson's disease (PD) are two of the most common neurodegenerative diseases and as such they represent major public health problems." | 2.46 | Caffeine protects against disruptions of the blood-brain barrier in animal models of Alzheimer's and Parkinson's diseases. ( Chen, X; Geiger, JD; Ghribi, O, 2010) |
| " We believe that the cognitive benefits of chronic caffeine administration in AD mice are due to caffeine itself, and not metabolites of caffeine; this, because our long-term administration of theophylline to AD mice provided no cognitive benefits." | 2.46 | Caffeine and coffee as therapeutics against Alzheimer's disease. ( Arendash, GW; Cao, C, 2010) |
| "Cilostazol (CSZ) has been shown to be a new treatment for cognitive impairment with limited efficacy." | 1.72 | Advancing combination treatment with cilostazol and caffeine for Alzheimer's disease in high fat-high fructose-STZ induced model of amnesia. ( Ahmed, AM; El-Mokhtar, MA; Farghaly, HSM; Gomaa, AA; Hemida, FK, 2022) |
| "Caffeine intake was inconsistently associated with clinical dementia; potentially explained by cohort differences in underlying dementia etiology." | 1.72 | Caffeine Consumption and Dementia: Are Lewy Bodies the Link? ( Bennett, DA; Cornelis, MC; Morris, MC; Schneider, JA; Weintraub, S, 2022) |
| "Amyloid-β, one of the hallmarks of Alzheimer's disease (AD), is toxic to neurons and can also cause brain cell death." | 1.51 | Ingredients in Zijuan Pu'er Tea Extract Alleviate β-Amyloid Peptide Toxicity in a ( Bai, S; Du, F; Fu, X; Jiao, Y; Ma, J; Wang, L; Zhou, L, 2019) |
| "Considering the complex etiology of Alzheimer's disease (AD), multifunctional agents may be beneficial for the treatment of this disease." | 1.46 | DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy. ( Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xu, R; Yang, X; Zheng, Y, 2017) |
| "As caffeine has been shown to be beneficial for diabetes, obesity and tau phosphorylation, we, therefore, used it as therapeutic treatment." | 1.46 | Tau hyperphosphorylation in the brain of ob/ob mice is due to hypothermia: Importance of thermoregulation in linking diabetes and Alzheimer's disease. ( Calon, F; El Khoury, NB; Gratuze, M; Julien, C; Marcouiller, F; Marette, A; Morin, F; Planel, E; Turgeon, A; Whittington, RA, 2017) |
| "Alzheimer's disease is the most common cause of dementia." | 1.42 | In Vitro Inhibitory Effects of 8-O-Demethylmaritidine and Undulatine on Acetylcholinesterase and Their Predicted Penetration across the Blood-Brain Barrier. ( Cahlíková, L; Chlebek, J; Hošt'álková, A; Opletal, L; Pérez, DI; Šafratová, M; Štěpánková, Š, 2015) |
| "Theobromine in the CSF was positively correlated with the levels of other xanthines in the CSF, but not in the plasma, suggesting that it may be formed by central metabolic pathways." | 1.42 | Does Caffeine Consumption Modify Cerebrospinal Fluid Amyloid-β Levels in Patients with Alzheimer's Disease? ( Agostinho, P; Baldeiras, I; Blennow, K; Cunha, RA; de Mendon, A; Gkatzima, O; Hasselbalch, SG; Kapaki, E; Manadas, B; Mara, B; Mendes, VM; Santana, I; Sermin, G; Simonsen, A; Travassos, M; Tsolaki, M; Yener, GG; Zetterberg, H, 2015) |
| "Tau pathology found in Alzheimer's disease (AD) is crucial in cognitive decline." | 1.40 | Beneficial effects of caffeine in a transgenic model of Alzheimer's disease-like tau pathology. ( Blum, D; Buée, L; Carrier, S; Demeyer, D; Derisbourg, M; Eddarkaoui, S; Hamdane, M; Laurent, C; Leboucher, A; Müller, CE; Schneider, M, 2014) |
| "5 mg/day doses of caffeine significantly increased memory capability and the expression of hippocampal BDNF and TrkB in PS1/APP mice with a dose-response effect." | 1.39 | Chronic caffeine treatment reverses memory impairment and the expression of brain BNDF and TrkB in the PS1/APP double transgenic mouse model of Alzheimer's disease. ( Han, K; Jia, N; Li, J; Min, LQ; Yang, L, 2013) |
| "Melatonin treatment yielded a near complete restoration of mitochondrial function in assays of respiratory rate, membrane potential, reactive oxygen species production, and ATP levels." | 1.38 | Caffeine increases mitochondrial function and blocks melatonin signaling to mitochondria in Alzheimer's mice and cells. ( Arendash, GW; Bradshaw, PC; Cao, C; Copes, N; Delic, V; Dragicevic, N; Lin, X; Mamcarz, M; Wang, L, 2012) |
| "Caffeine intake was determined according to self-reported coffee, tea, and cola consumption at baseline." | 1.37 | Coffee intake in midlife and risk of dementia and its neuropathologic correlates. ( Gelber, RP; Masaki, KH; Petrovitch, H; Ross, GW; White, LR, 2011) |
| "Caffeine treatment stimulated PKA activity, increased phospho-CREB levels, and decreased phospho-JNK and phospho-ERK expression in the striatum of APPswe mice, all of which are thought to be beneficial changes for brain function." | 1.37 | Caffeine induces beneficial changes in PKA signaling and JNK and ERK activities in the striatum and cortex of Alzheimer's transgenic mice. ( Arendash, GW; Burgess, S; Echeverria, V; Patel, S; Zeitlin, R, 2011) |
| "Dementia and Alzheimer's disease (AD) are rapidly increasing public health problems in ageing populations and at the moment curative treatment is lacking." | 1.36 | Caffeine as a protective factor in dementia and Alzheimer's disease. ( Eskelinen, MH; Kivipelto, M, 2010) |
| "Caffeine has antioxidant properties and has been demonstrated to reduce Abeta levels in transgenic mouse models of familial AD." | 1.36 | Caffeine protects against oxidative stress and Alzheimer's disease-like pathology in rabbit hippocampus induced by cholesterol-enriched diet. ( Chen, X; Dasari, B; Geiger, JD; Ghribi, O; Larson, T; Marwarha, G; Prasanthi, JR, 2010) |
| "We have recently shown that Alzheimer's disease (AD) transgenic mice given a moderate level of caffeine intake (the human equivalent of 5 cups of coffee per day) are protected from development of otherwise certain cognitive impairment and have decreased hippocampal amyloid-beta (Abeta) levels due to suppression of both beta-secretase (BACE1) and presenilin 1 (PS1)/gamma-secretase expression." | 1.35 | Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice. ( Arendash, GW; Cao, C; Citron, BA; Dickson, A; Echeverria, V; Lin, X; Mamcarz, M; Mori, T; Potter, H; Rezai-Zadeh, K; Runfeldt, M; Tane, J, 2009) |
| "Psychosis frequently occurs in Alzheimer's disease (AD), being associated with more severe cognitive decline, but the underlying mechanisms are unknown." | 1.32 | Beta-amyloid treatment sensitizes mice to amphetamine-induced locomotion but reduces response to caffeine. ( da Silva, AL; Dall'Igna, OP; Hoffmann, A; Lara, DR; Souza, DO, 2004) |
| "Caffeine intake was associated with a significantly lower risk for AD, independently of other possible confounding variables." | 1.31 | Does caffeine intake protect from Alzheimer's disease? ( de Mendonça, A; Maia, L, 2002) |
| "The implication is that if Alzheimer's disease is a cholinergic disorder, it may be amenable to transport-directed chemotherapies." | 1.28 | Studies on choline transport enhancement into fibroblasts from normals and Alzheimer's donors. ( Mokrasch, LC, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.79) | 18.7374 |
| 1990's | 4 (3.15) | 18.2507 |
| 2000's | 21 (16.54) | 29.6817 |
| 2010's | 71 (55.91) | 24.3611 |
| 2020's | 30 (23.62) | 2.80 |
| Authors | Studies |
|---|---|
| Marco-Contelles, J | 1 |
| León, R | 3 |
| de los Ríos, C | 1 |
| Samadi, A | 1 |
| Bartolini, M | 2 |
| Andrisano, V | 3 |
| Huertas, O | 2 |
| Barril, X | 1 |
| Luque, FJ | 2 |
| Rodríguez-Franco, MI | 6 |
| López, B | 3 |
| López, MG | 4 |
| García, AG | 3 |
| Carreiras, Mdo C | 1 |
| Villarroya, M | 4 |
| Camps, P | 1 |
| Formosa, X | 1 |
| Galdeano, C | 1 |
| Muñoz-Torrero, D | 1 |
| Ramírez, L | 1 |
| Gómez, E | 1 |
| Isambert, N | 1 |
| Lavilla, R | 1 |
| Badia, A | 1 |
| Clos, MV | 1 |
| Mancini, F | 2 |
| Arce, MP | 4 |
| Dafni, T | 1 |
| González-Muñoz, GC | 2 |
| Pérez, C | 4 |
| Conde, S | 3 |
| Romero, A | 1 |
| del Barrio, L | 1 |
| Martín-de-Saavedra, MD | 1 |
| Egea, J | 2 |
| Tang, H | 3 |
| Zhao, LZ | 1 |
| Zhao, HT | 2 |
| Huang, SL | 1 |
| Zhong, SM | 2 |
| Qin, JK | 1 |
| Chen, ZF | 2 |
| Huang, ZS | 1 |
| Liang, H | 2 |
| Chiriano, G | 1 |
| De Simone, A | 1 |
| Perez, DI | 2 |
| Cavalli, A | 1 |
| Bolognesi, ML | 1 |
| Legname, G | 1 |
| Martinez, A | 1 |
| Carloni, P | 1 |
| Roberti, M | 1 |
| Wang, ZY | 1 |
| Sang, Z | 11 |
| Li, Y | 12 |
| Qiang, X | 10 |
| Xiao, G | 7 |
| Liu, Q | 2 |
| Tan, Z | 12 |
| Deng, Y | 11 |
| Xie, SS | 4 |
| Wang, X | 1 |
| Jiang, N | 3 |
| Yu, W | 1 |
| Wang, KD | 1 |
| Lan, JS | 1 |
| Li, ZR | 1 |
| Kong, LY | 1 |
| Cahlíková, L | 1 |
| Štěpánková, Š | 1 |
| Chlebek, J | 1 |
| Šafratová, M | 1 |
| Hošt'álková, A | 1 |
| Opletal, L | 1 |
| Luo, L | 6 |
| Wei, S | 1 |
| Chen, W | 1 |
| Qin, J | 1 |
| Huangli, Y | 1 |
| Wang, L | 7 |
| Shen, Y | 1 |
| Yang, X | 5 |
| Zheng, Y | 4 |
| Cao, Z | 7 |
| Su, F | 2 |
| Ai, J | 1 |
| Xu, R | 5 |
| Song, Q | 5 |
| Monjas, L | 1 |
| Gil, C | 1 |
| Pan, W | 2 |
| Wang, K | 8 |
| Ma, Q | 4 |
| Yu, L | 4 |
| Yang, Y | 1 |
| Bai, P | 2 |
| Leng, C | 1 |
| Xu, Q | 1 |
| Li, X | 2 |
| Liu, W | 10 |
| Wang, H | 6 |
| Ye, M | 2 |
| Han, X | 2 |
| Xu, YX | 1 |
| Li, XK | 1 |
| Dong, SN | 1 |
| Liu, WW | 1 |
| Gong, Q | 2 |
| Wang, TD | 1 |
| Tang, Y | 1 |
| Zhu, J | 2 |
| Li, J | 3 |
| Zhang, HY | 1 |
| Mao, F | 2 |
| Huang, Q | 1 |
| Liu, J | 3 |
| Liang, N | 2 |
| Li, Q | 3 |
| Yang, J | 2 |
| Zhang, X | 3 |
| Liu, H | 4 |
| Yang, Z | 2 |
| Xu, Y | 1 |
| Zhang, J | 1 |
| Wang, W | 1 |
| Qiu, X | 1 |
| Zhang, H | 1 |
| Reis, J | 1 |
| Cagide, F | 1 |
| Valencia, ME | 1 |
| Teixeira, J | 1 |
| Bagetta, D | 1 |
| Uriarte, E | 1 |
| Oliveira, PJ | 1 |
| Ortuso, F | 1 |
| Alcaro, S | 1 |
| Borges, F | 1 |
| Tian, C | 1 |
| Li, W | 1 |
| He, Y | 1 |
| Ye, C | 1 |
| Shi, J | 5 |
| Zhang, P | 3 |
| Zhu, G | 1 |
| Yang, D | 1 |
| Fan, X | 1 |
| Zhang, Z | 3 |
| Cheng, X | 1 |
| Zhang, Q | 1 |
| Zheng, C | 1 |
| Cheng, Y | 1 |
| Lu, X | 1 |
| Tang, C | 1 |
| Pang, C | 1 |
| Qin, Y | 1 |
| Nong, X | 1 |
| Guo, J | 2 |
| Cheng, M | 2 |
| Tang, W | 1 |
| Zhou, W | 1 |
| Wan, Y | 1 |
| Wang, R | 1 |
| Fang, Y | 1 |
| Jin, Y | 1 |
| Manzoor, S | 1 |
| Prajapati, SK | 1 |
| Majumdar, S | 1 |
| Raza, MK | 1 |
| Gabr, MT | 1 |
| Kumar, S | 2 |
| Pal, K | 1 |
| Rashid, H | 1 |
| Krishnamurthy, S | 1 |
| Hoda, N | 1 |
| Liu, X | 1 |
| Tian, L | 1 |
| Gao, Y | 1 |
| Chen, H | 1 |
| Jiang, X | 1 |
| Xu, Z | 1 |
| Ding, H | 1 |
| Zhao, Q | 2 |
| Kim, E | 1 |
| Robinson, NM | 1 |
| Newman, BM | 1 |
| Merighi, S | 2 |
| Borea, PA | 2 |
| Varani, K | 2 |
| Vincenzi, F | 2 |
| Jacobson, KA | 1 |
| Gessi, S | 2 |
| Stazi, M | 2 |
| Lehmann, S | 1 |
| Sakib, MS | 1 |
| Pena-Centeno, T | 1 |
| Büschgens, L | 1 |
| Fischer, A | 1 |
| Weggen, S | 1 |
| Wirths, O | 2 |
| Janitschke, D | 4 |
| Lauer, AA | 4 |
| Bachmann, CM | 3 |
| Winkler, J | 2 |
| Griebsch, LV | 1 |
| Pilz, SM | 1 |
| Theiss, EL | 1 |
| Grimm, HS | 4 |
| Hartmann, T | 4 |
| Grimm, MOW | 4 |
| Gomaa, AA | 1 |
| Farghaly, HSM | 1 |
| Ahmed, AM | 1 |
| El-Mokhtar, MA | 1 |
| Hemida, FK | 1 |
| Cornelis, MC | 1 |
| Bennett, DA | 1 |
| Weintraub, S | 1 |
| Schneider, JA | 1 |
| Morris, MC | 1 |
| Larsson, SC | 1 |
| Woolf, B | 1 |
| Gill, D | 1 |
| Ryu, WI | 1 |
| Shen, M | 1 |
| Lee, Y | 1 |
| Healy, RA | 1 |
| Bormann, MK | 1 |
| Cohen, BM | 1 |
| Sonntag, KC | 1 |
| M Yelanchezian, YM | 1 |
| Waldvogel, HJ | 1 |
| Faull, RLM | 1 |
| Kwakowsky, A | 1 |
| Sharma, M | 2 |
| Sharma, A | 2 |
| Nuthakki, VK | 2 |
| Bhatt, S | 1 |
| Nandi, U | 2 |
| Bharate, SB | 2 |
| Zampar, S | 1 |
| Klafki, HW | 1 |
| Meyer, T | 1 |
| Dong, R | 1 |
| Denier-Fields, DN | 1 |
| Van Hulle, CA | 1 |
| Kollmorgen, G | 1 |
| Suridjan, I | 1 |
| Wild, N | 1 |
| Lu, Q | 1 |
| Anderson, RM | 1 |
| Zetterberg, H | 2 |
| Blennow, K | 2 |
| Carlsson, CM | 1 |
| Johnson, SC | 1 |
| Engelman, CD | 1 |
| Zheng, YB | 1 |
| Sun, J | 1 |
| Shi, L | 1 |
| Su, SZ | 1 |
| Chen, X | 4 |
| Wang, QW | 1 |
| Huang, YT | 1 |
| Wang, YJ | 1 |
| Zhu, XM | 1 |
| Que, JY | 1 |
| Zeng, N | 1 |
| Lin, X | 6 |
| Yuan, K | 1 |
| Yan, W | 1 |
| Deng, JH | 1 |
| Bao, YP | 1 |
| Lu, L | 1 |
| Grzelczyk, J | 1 |
| Szwajgier, D | 1 |
| Baranowska-Wójcik, E | 1 |
| Pérez-Sánchez, H | 1 |
| Carmena-Bargueño, M | 1 |
| Sosnowska, B | 1 |
| Budryn, G | 1 |
| Travagli, A | 1 |
| Nigro, M | 1 |
| Pasquini, S | 1 |
| Cappello, M | 1 |
| Contri, C | 1 |
| Tira, R | 1 |
| Viola, G | 1 |
| Barracchia, CG | 1 |
| Parolini, F | 1 |
| Munari, F | 1 |
| Capaldi, S | 1 |
| Assfalg, M | 1 |
| D'Onofrio, M | 1 |
| Thakur, S | 1 |
| Jamwal, A | 1 |
| Jadhav, HR | 1 |
| Matsumura, N | 1 |
| Aoyama, K | 1 |
| Minné, D | 1 |
| Stromin, J | 1 |
| Docrat, T | 1 |
| Engel-Hills, P | 1 |
| Marnewick, JL | 1 |
| Adjetey, C | 1 |
| Davis, JC | 1 |
| Falck, RS | 1 |
| Best, JR | 1 |
| Dao, E | 1 |
| Bennett, K | 1 |
| Tai, D | 1 |
| McGuire, K | 1 |
| Eng, JJ | 1 |
| Hsiung, GR | 1 |
| Middleton, LE | 1 |
| Hall, PA | 1 |
| Hu, M | 1 |
| Sakakibara, BM | 1 |
| Liu-Ambrose, T | 1 |
| Nelke, C | 1 |
| Regner, L | 1 |
| Thiel, A | 1 |
| Seyfried, M | 1 |
| Pan, L | 1 |
| Ma, Y | 1 |
| Wu, H | 1 |
| Huang, R | 1 |
| Cai, Z | 1 |
| Wu, X | 1 |
| Londzin, P | 1 |
| Zamora, M | 1 |
| Kąkol, B | 1 |
| Taborek, A | 1 |
| Folwarczna, J | 1 |
| Zhang, Y | 1 |
| Yang, H | 1 |
| Li, S | 1 |
| Li, WD | 1 |
| Yan, T | 1 |
| Wang, Y | 2 |
| Zhou, X | 1 |
| Zhang, L | 1 |
| Toussay, X | 1 |
| Morel, JL | 1 |
| Biendon, N | 1 |
| Rotureau, L | 1 |
| Legeron, FP | 1 |
| Boutonnet, MC | 1 |
| Cho, YH | 1 |
| Macrez, N | 1 |
| Hussain, A | 1 |
| Tabrez, ES | 1 |
| Mavrych, V | 1 |
| Bolgova, O | 1 |
| Peela, JR | 1 |
| Cova, I | 1 |
| Leta, V | 1 |
| Mariani, C | 1 |
| Pantoni, L | 1 |
| Pomati, S | 1 |
| Du, F | 1 |
| Zhou, L | 1 |
| Jiao, Y | 1 |
| Bai, S | 1 |
| Ma, J | 1 |
| Fu, X | 1 |
| Andrade, S | 1 |
| Ramalho, MJ | 1 |
| Loureiro, JA | 1 |
| Pereira, MC | 1 |
| Szczechowiak, K | 1 |
| Diniz, BS | 1 |
| Leszek, J | 1 |
| Han, K | 1 |
| Jia, N | 1 |
| Yang, L | 1 |
| Min, LQ | 1 |
| Flaten, V | 1 |
| Laurent, C | 2 |
| Coelho, JE | 1 |
| Sandau, U | 1 |
| Batalha, VL | 2 |
| Burnouf, S | 1 |
| Hamdane, M | 2 |
| Humez, S | 1 |
| Boison, D | 1 |
| Lopes, LV | 2 |
| Buée, L | 2 |
| Blum, D | 2 |
| Carman, AJ | 1 |
| Dacks, PA | 1 |
| Lane, RF | 1 |
| Shineman, DW | 1 |
| Fillit, HM | 1 |
| Eddarkaoui, S | 1 |
| Derisbourg, M | 1 |
| Leboucher, A | 1 |
| Demeyer, D | 1 |
| Carrier, S | 1 |
| Schneider, M | 1 |
| Müller, CE | 1 |
| Beydoun, MA | 1 |
| Beydoun, HA | 1 |
| Gamaldo, AA | 1 |
| Teel, A | 1 |
| Zonderman, AB | 1 |
| Walters, ER | 1 |
| Lesk, VE | 1 |
| Kim, YS | 1 |
| Kwak, SM | 1 |
| Myung, SK | 1 |
| Panza, F | 1 |
| Solfrizzi, V | 1 |
| Barulli, MR | 1 |
| Bonfiglio, C | 1 |
| Guerra, V | 1 |
| Osella, A | 1 |
| Seripa, D | 1 |
| Sabbà, C | 1 |
| Pilotto, A | 1 |
| Logroscino, G | 1 |
| Ghoneim, FM | 1 |
| Khalaf, HA | 1 |
| Elsamanoudy, AZ | 1 |
| Abo El-Khair, SM | 1 |
| Helaly, AM | 1 |
| Mahmoud, el-HM | 1 |
| Elshafey, SH | 1 |
| Travassos, M | 1 |
| Santana, I | 1 |
| Baldeiras, I | 1 |
| Tsolaki, M | 1 |
| Gkatzima, O | 1 |
| Sermin, G | 1 |
| Yener, GG | 1 |
| Simonsen, A | 1 |
| Hasselbalch, SG | 1 |
| Kapaki, E | 1 |
| Mara, B | 1 |
| Cunha, RA | 7 |
| Agostinho, P | 1 |
| Mendes, VM | 1 |
| Manadas, B | 1 |
| de Mendon, A | 1 |
| Lee, M | 1 |
| McGeer, EG | 1 |
| McGeer, PL | 1 |
| Sharma, B | 1 |
| Paul, S | 1 |
| Gratuze, M | 1 |
| El Khoury, NB | 1 |
| Turgeon, A | 1 |
| Julien, C | 1 |
| Marcouiller, F | 1 |
| Morin, F | 1 |
| Whittington, RA | 1 |
| Marette, A | 1 |
| Calon, F | 1 |
| Planel, E | 1 |
| Vandenberghe, C | 1 |
| St-Pierre, V | 1 |
| Courchesne-Loyer, A | 1 |
| Hennebelle, M | 1 |
| Castellano, CA | 1 |
| Cunnane, SC | 1 |
| Tabaton, M | 1 |
| Arendash, GW | 8 |
| Mori, T | 2 |
| Cao, C | 6 |
| Mamcarz, M | 4 |
| Runfeldt, M | 1 |
| Dickson, A | 2 |
| Rezai-Zadeh, K | 2 |
| Tane, J | 1 |
| Citron, BA | 1 |
| Echeverria, V | 2 |
| Potter, H | 4 |
| Cirrito, JR | 1 |
| Verges, DK | 1 |
| Zhang, C | 3 |
| Holtzman, DM | 1 |
| Franco, R | 1 |
| Canas, PM | 1 |
| Porciúncula, LO | 2 |
| Cunha, GM | 1 |
| Silva, CG | 1 |
| Machado, NJ | 1 |
| Oliveira, JM | 1 |
| Oliveira, CR | 1 |
| Ghribi, O | 3 |
| Geiger, JD | 3 |
| Eskelinen, MH | 1 |
| Kivipelto, M | 1 |
| de Mendonça, A | 3 |
| Prasanthi, JR | 1 |
| Dasari, B | 1 |
| Marwarha, G | 1 |
| Larson, T | 1 |
| Goussakov, I | 1 |
| Miller, MB | 1 |
| Stutzmann, GE | 1 |
| Chen, JF | 1 |
| Chern, Y | 1 |
| Gelber, RP | 1 |
| Petrovitch, H | 1 |
| Masaki, KH | 1 |
| Ross, GW | 1 |
| White, LR | 1 |
| Bai, G | 2 |
| Nong, J | 1 |
| Sussman, S | 1 |
| Arendash, G | 1 |
| Marques, S | 1 |
| Outeiro, TF | 1 |
| Abuznait, AH | 1 |
| Cain, C | 1 |
| Ingram, D | 1 |
| Burk, D | 1 |
| Kaddoumi, A | 1 |
| Zeitlin, R | 1 |
| Patel, S | 1 |
| Burgess, S | 1 |
| Loewenstein, DA | 1 |
| Duara, R | 1 |
| Wu, Y | 1 |
| Giannini, A | 1 |
| Cai, J | 1 |
| Greig, M | 1 |
| Schofield, E | 1 |
| Ashok, R | 1 |
| Small, B | 1 |
| Oulès, B | 1 |
| Del Prete, D | 1 |
| Greco, B | 1 |
| Lauritzen, I | 1 |
| Sevalle, J | 1 |
| Moreno, S | 1 |
| Paterlini-Bréchot, P | 1 |
| Trebak, M | 1 |
| Checler, F | 1 |
| Benfenati, F | 1 |
| Chami, M | 1 |
| Chu, YF | 1 |
| Chang, WH | 1 |
| Black, RM | 1 |
| Liu, JR | 1 |
| Sompol, P | 1 |
| Chen, Y | 1 |
| Wei, H | 1 |
| Cheng, IH | 1 |
| Dragicevic, N | 1 |
| Delic, V | 1 |
| Copes, N | 1 |
| Bradshaw, PC | 1 |
| Hermansen, K | 1 |
| Krogholm, KS | 1 |
| Bech, BH | 1 |
| Dragsted, LO | 1 |
| Hyldstrup, L | 1 |
| Jørgensen, K | 1 |
| Larsen, ML | 1 |
| Tjønneland, AM | 1 |
| Dall'Igna, OP | 4 |
| Souza, DO | 4 |
| Lara, DR | 4 |
| Dall'lgna, OP | 1 |
| Hall, SS | 1 |
| Smith, IF | 1 |
| Hitt, B | 1 |
| Green, KN | 1 |
| Oddo, S | 1 |
| LaFerla, FM | 1 |
| Hoffmann, A | 1 |
| da Silva, AL | 1 |
| Schleif, W | 1 |
| Jackson, EK | 1 |
| Zacharia, LC | 1 |
| Cracchiolo, JR | 2 |
| Shippy, D | 1 |
| Tan, J | 1 |
| Fett, P | 1 |
| Gomes, MW | 1 |
| Daly, JW | 1 |
| Leighty, RE | 1 |
| Runfeldt, MJ | 1 |
| Berndt, DJ | 1 |
| Schleif, WS | 1 |
| Chin, JH | 1 |
| Tse, FW | 1 |
| Harris, K | 1 |
| Jhamandas, JH | 1 |
| Gawryluk, JW | 1 |
| Wagener, JF | 1 |
| Schelling, JL | 1 |
| Parshad, RP | 1 |
| Sanford, KK | 1 |
| Price, FM | 1 |
| Melnick, LK | 1 |
| Nee, LE | 1 |
| Schapiro, MB | 1 |
| Tarone, RE | 1 |
| Robbins, JH | 1 |
| Fontana, RJ | 2 |
| Turgeon, DK | 1 |
| Woolf, TF | 2 |
| Knapp, MJ | 2 |
| Foster, NL | 2 |
| Watkins, PB | 2 |
| deVries, TM | 1 |
| Brown, AS | 1 |
| Kaminsky, LS | 1 |
| Tang, BK | 1 |
| Brown, RR | 1 |
| Maia, L | 1 |
| Mokrasch, LC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Crossover Study to Investigate the Safety and Efficacy of Qualia Mind on Cognition in a Healthy Population[NCT04389723] | 60 participants (Actual) | Interventional | 2020-05-12 | Completed | |||
| A Pilot, Randomized, Double-blind, Placebo-controlled, Parallel Design Study to Evaluate the Effectiveness and Safety of an Alpinia Galanga Formulation, Theacrine Formulation, and Caffeine Formulation on Fatigue, Mental Acuity, and Cognitive Health Among [NCT05170113] | 79 participants (Actual) | Interventional | 2021-11-02 | Completed | |||
| Vitamin D Status and Intakes and Their Association With Cognitive Trajectory in a Longitudinal Study of Urban Adults[NCT03320109] | 3,720 participants (Actual) | Observational | 2004-08-18 | Completed | |||
| The Impact of Caffeine on Cognition in Schizophrenia[NCT02832401] | 24 participants (Actual) | Interventional | 2016-09-02 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
24 reviews available for caffeine and Alzheimer Disease
| Article | Year |
|---|---|
A Brewed Awakening: Neuropsychiatric Effects of Caffeine in Older Adults.
Topics: Aged; Alzheimer Disease; Caffeine; Humans; Parkinson Disease; Psychotropic Drugs; Sleep Initiation a | 2022 |
A
Topics: Adenosine A2 Receptor Antagonists; Alzheimer Disease; Amyloid beta-Peptides; Animals; Caffeine; Huma | 2022 |
Neuroprotective Effect of Caffeine in Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Caffeine; Coffee; Cognition Disorders; Humans; Neuroprotective Agents | 2022 |
Caffeine for Prevention of Alzheimer's Disease: Is the A
Topics: Alzheimer Disease; Caffeine; Coffee; Cognitive Dysfunction; Humans; Neuroprotective Agents; Receptor | 2023 |
Glutathione-Mediated Neuroprotective Effect of Purine Derivatives.
Topics: Adenosine A2 Receptor Antagonists; Alzheimer Disease; Brain; Caffeine; Cysteine; Excitatory Amino Ac | 2023 |
The effects of tea polyphenols on emotional homeostasis: Understanding dementia risk through stress, mood, attention & sleep.
Topics: Affect; Alzheimer Disease; Caffeine; Homeostasis; Humans; Tea | 2023 |
The Therapeutic Potential of Purinergic Receptors in Alzheimer's Disease and Promising Therapeutic Modulators.
Topics: Adenosine; Alzheimer Disease; Caffeine; Humans; Protein Isoforms; Purinergic Agonists; Purinergic An | 2021 |
Potential of Caffeine in Alzheimer's Disease-A Review of Experimental Studies.
Topics: Alzheimer Disease; Animals; Caffeine; Cognition; Cognitive Dysfunction; Humans | 2021 |
Methylxanthines and Neurodegenerative Diseases: An Update.
Topics: Alzheimer Disease; Animals; Caffeine; Coffee; Humans; Multiple Sclerosis; Neurodegenerative Diseases | 2021 |
The Neuroprotective Effects of Moderate and Regular Caffeine Consumption in Alzheimer's Disease.
Topics: Aged; Alzheimer Disease; Animals; Caffeine; Coffee; Humans; Neuroprotective Agents; Risk Factors; Te | 2021 |
Caffeine: A Potential Protective Agent Against Cognitive Decline in Alzheimer's Disease.
Topics: Alzheimer Disease; Caffeine; Central Nervous System Stimulants; Cognitive Dysfunction; Humans; Prote | 2018 |
Exploring cocoa properties: is theobromine a cognitive modulator?
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cacao; Caffeine; Central Nervous System Stimulant | 2019 |
Diet and Alzheimer's dementia - Nutritional approach to modulate inflammation.
Topics: Alzheimer Disease; Butyrates; Caffeine; Cholecalciferol; Curcumin; Diet; Dietary Supplements; Enceph | 2019 |
From epidemiology to pathophysiology: what about caffeine in Alzheimer's disease?
Topics: Alzheimer Disease; Animals; Caffeine; Humans; Purinergic P1 Receptor Antagonists; Receptors, Puriner | 2014 |
Current evidence for the use of coffee and caffeine to prevent age-related cognitive decline and Alzheimer's disease.
Topics: Aging; Alzheimer Disease; Animals; Caffeine; Coffee; Cognition; Cognition Disorders; Humans; Memory, | 2014 |
Epidemiologic studies of modifiable factors associated with cognition and dementia: systematic review and meta-analysis.
Topics: Alcohol Drinking; Alzheimer Disease; Antioxidants; Caffeine; Cognition; Cognition Disorders; Dementi | 2014 |
Caffeine intake from coffee or tea and cognitive disorders: a meta-analysis of observational studies.
Topics: Alzheimer Disease; Caffeine; Case-Control Studies; Coffee; Cognition Disorders; Cohort Studies; Deme | 2015 |
Coffee, tea, and caffeine consumption and prevention of late-life cognitive decline and dementia: a systematic review.
Topics: Alzheimer Disease; Caffeine; Coffee; Cognition; Cognition Disorders; Cognitive Dysfunction; Dementia | 2015 |
[Caffeine, adenosine receptors, memory and Alzheimer disease].
Topics: Alzheimer Disease; Animals; Caffeine; Humans; Memory; Purinergic P1 Receptor Antagonists | 2008 |
Caffeine protects against disruptions of the blood-brain barrier in animal models of Alzheimer's and Parkinson's diseases.
Topics: Alzheimer Disease; Animals; Blood-Brain Barrier; Caffeine; Disease Models, Animal; Humans; Parkinson | 2010 |
Caffeine and coffee as therapeutics against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Caffeine; C | 2010 |
Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies.
Topics: Alzheimer Disease; Animals; Brain Injuries; Caffeine; Humans; Huntington Disease; Neurodegenerative | 2011 |
Modulating Alzheimer's disease through caffeine: a putative link to epigenetics.
Topics: Adenosine A2 Receptor Antagonists; Aging; Alzheimer Disease; Animals; Caffeine; Epigenesis, Genetic; | 2011 |
Caffeine analogs: biomedical impact.
Topics: Alzheimer Disease; Asthma; Biomedical Research; Caffeine; Calcium; Central Nervous System Stimulants | 2007 |
5 trials available for caffeine and Alzheimer Disease
| Article | Year |
|---|---|
Economic Evaluation of Exercise or Cognitive and Social Enrichment Activities for Improved Cognition After Stroke.
Topics: Aged; Alzheimer Disease; British Columbia; Caffeine; Cognition; Cost-Benefit Analysis; Exercise; Fem | 2023 |
Time of day and caffeine influence some neuropsychological tests in the elderly.
Topics: Aged; Alzheimer Disease; Caffeine; Circadian Rhythm; Dementia; Female; Humans; Male; Neuropsychologi | 2015 |
Caffeine intake increases plasma ketones: an acute metabolic study in humans.
Topics: Adult; Aging; Alzheimer Disease; Brain; Caffeine; Dietary Supplements; Dose-Response Relationship, D | 2017 |
The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity.
Topics: Aged; Aged, 80 and over; Alanine Transaminase; Alzheimer Disease; Breath Tests; Caffeine; Cholineste | 1996 |
Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer's disease.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Caffeine; Cholinesterase Inhibitor | 1998 |
98 other studies available for caffeine and Alzheimer Disease
| Article | Year |
|---|---|
Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Blood-Brain Barrier; Butyrylcholines | 2009 |
Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases | 2009 |
Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cataly | 2009 |
N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antineoplastic Agents; Butyrylcholinesterase; Calcium; Cel | 2011 |
Hybrids of oxoisoaporphine-tacrine congeners: novel acetylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Aporphines; Blood- | 2011 |
A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Cell Surviv | 2012 |
Novel oxoisoaporphine-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Aporphines; Binding Sites; Blood-Bra | 2012 |
Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Apigenin; Blood-Brain Barrier; Butyr | 2015 |
Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Benzopyrans; Blood-Brain Barrier; Brain; Cell Survival; Cel | 2015 |
In Vitro Inhibitory Effects of 8-O-Demethylmaritidine and Undulatine on Acetylcholinesterase and Their Predicted Penetration across the Blood-Brain Barrier.
Topics: Acetylcholinesterase; Alzheimer Disease; Amaryllidaceae Alkaloids; Biological Transport; Blood-Brain | 2015 |
Synthesis and evaluation of 4-hydroxyl aurone derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Benzofurans; Blood-Brain Barrier; C | 2016 |
Multitarget-directed oxoisoaporphine derivatives: Anti-acetylcholinesterase, anti-β-amyloid aggregation and enhanced autophagy activity against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Aporphines; Autophagy; Cholinesteras | 2016 |
Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug | 2017 |
Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; D | 2017 |
Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Chalcones; Cholinesterase Inh | 2017 |
DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipyrine; Benzofurans; Binding Sites; Bloo | 2017 |
Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Cell Line; Cholinesterase Inhibitors | 2017 |
Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.
Topics: Alzheimer Disease; Animals; Brain Ischemia; Calcium Channel Blockers; Cholinesterase Inhibitors; Don | 2017 |
Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Butyrylcholine | 2017 |
Design, synthesis and biological evaluation of 3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cholin | 2017 |
Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amines; Binding Sites; Blood-Brain Barrier; Cell Line, Tumor; Cell Survival; Chol | 2017 |
Design, synthesis and biological evaluation of 2-acetyl-5-O-(amino-alkyl)phenol derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Benzophenones; Binding Sites; Blood- | 2017 |
Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; | 2018 |
Design, synthesis and biological evaluation of new coumarin-dithiocarbamate hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell L | 2018 |
Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Line; Cell Surviva | 2018 |
Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Benzylamines; Blood-Br | 2018 |
Design, synthesis and evaluation of vilazodone-tacrine hybrids as multitarget-directed ligands against depression with cognitive impairment.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cholin | 2018 |
Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
Topics: Alzheimer Disease; Blood-Brain Barrier; Cholinesterase Inhibitors; Cholinesterases; Chromones; Drug | 2018 |
Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, N | 2018 |
Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Cell Line; Cho | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Butyry | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Chalcone; Cholinesterase I | 2019 |
The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Drug Design; Drug Developm | 2019 |
Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Biological Tr | 2019 |
Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Line, Tumor; Cell Survival; Clorgyline; Dose | 2020 |
Design, synthesis, and biological evaluation of novel xanthone-alkylbenzylamine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Benzothiazoles; Benzylamines; Biphen | 2021 |
Discovery of new phenyl sulfonyl-pyrimidine carboxylate derivatives as the potential multi-target drugs with effective anti-Alzheimer's action: Design, synthesis, crystal structure and in-vitro biological evaluation.
Topics: Acetylcholinesterase; Alzheimer Disease; Blood-Brain Barrier; Butyrylcholinesterase; Cell Line, Tumo | 2021 |
Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Dyr | 2021 |
Long-term caffeine treatment of Alzheimer mouse models ameliorates behavioural deficits and neuron loss and promotes cellular and molecular markers of neurogenesis.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Biomarkers; Caffeine; Cells, Cultured; Female; Ma | 2021 |
Methylxanthines Induce a Change in the AD/Neurodegeneration-Linked Lipid Profile in Neuroblastoma Cells.
Topics: Alzheimer Disease; Caffeine; Cell Line, Tumor; Cholesterol; Humans; Lipids; Neural Stem Cells; Neuro | 2022 |
Advancing combination treatment with cilostazol and caffeine for Alzheimer's disease in high fat-high fructose-STZ induced model of amnesia.
Topics: Alzheimer Disease; Amnesia; Amyloid beta-Peptides; Animals; Caffeine; Cilostazol; Diabetes Mellitus, | 2022 |
Caffeine Consumption and Dementia: Are Lewy Bodies the Link?
Topics: Alzheimer Disease; Caffeine; Cognitive Dysfunction; Humans; Lewy Bodies; Neuropsychological Tests | 2022 |
Plasma Caffeine Levels and Risk of Alzheimer's Disease and Parkinson's Disease: Mendelian Randomization Study.
Topics: Alzheimer Disease; Caffeine; Genome-Wide Association Study; Humans; Mendelian Randomization Analysis | 2022 |
Nicotinamide riboside and caffeine partially restore diminished NAD availability but not altered energy metabolism in Alzheimer's disease.
Topics: Alzheimer Disease; Caffeine; Energy Metabolism; Humans; NAD; Niacinamide; Pyridinium Compounds | 2022 |
Design, synthesis, and structure-activity relationship of caffeine-based triazoles as dual AChE and BACE-1 inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Biological Products; Caffeine; Cholinesterase Inhibitors; H | 2022 |
A Combination of Caffeine Supplementation and Enriched Environment in an Alzheimer's Disease Mouse Model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Caffeine; Dietary | 2023 |
Identification of plasma metabolites associated with modifiable risk factors and endophenotypes reflecting Alzheimer's disease pathology.
Topics: Adult; Alzheimer Disease; Amyloid beta-Peptides; Beta-Cryptoxanthin; Biomarkers; Caffeine; Endopheno | 2023 |
Association of Caffeine Consumption and Brain Amyloid Positivity in Cognitively Normal Older Adults.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Amyloidogenic Proteins; Brain; Caffeine; Cross-Secti | 2023 |
Effect of Inhibiting Butyrylcholinesterase Activity Using Fractionated Coffee Extracts Digested In Vitro in Gastrointestinal Tract: Docking Simulation and Calorimetric and Studies.
Topics: Alzheimer Disease; Butyrylcholinesterase; Caffeine; Calorimetry; Cholinesterase Inhibitors; Gastroin | 2023 |
Espresso Coffee Mitigates the Aggregation and Condensation of Alzheimer's Associated Tau Protein.
Topics: Alzheimer Disease; Caffeine; Humans; Plant Extracts; tau Proteins; Tauopathies | 2023 |
Discovery of blood-brain barrier permeable and orally bioavailable caffeine-based amide derivatives as acetylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Amides; Animals; Blood-Brain Barrier; Caffeine; Cholinester | 2023 |
Effect of Caffeine and Other Methylxanthines on Aβ-Homeostasis in SH-SY5Y Cells.
Topics: ADAM10 Protein; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Pr | 2019 |
Unique Role of Caffeine Compared to Other Methylxanthines (Theobromine, Theophylline, Pentoxifylline, Propentofylline) in Regulation of AD Relevant Genes in Neuroblastoma SH-SY5Y Wild Type Cells.
Topics: Alzheimer Disease; Caffeine; Cell Line, Tumor; Gene Expression Regulation; Genes, Essential; Humans; | 2020 |
Association of coffee and genetic risk with incident dementia in middle-aged and elderly adults.
Topics: Adult; Aged; Alzheimer Disease; Caffeine; Dementia, Vascular; Humans; Middle Aged; Prospective Studi | 2022 |
Presenilin 1 mutation decreases both calcium and contractile responses in cerebral arteries.
Topics: Alzheimer Disease; Animals; Caffeine; Calcium; Calcium Signaling; Calcium-Binding Proteins; Cerebral | 2017 |
Ingredients in Zijuan Pu'er Tea Extract Alleviate β-Amyloid Peptide Toxicity in a
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Genetically Modified; Antioxidants; Bifl | 2019 |
Interaction of natural compounds with biomembrane models: A biophysical approach for the Alzheimer's disease therapy.
Topics: Alzheimer Disease; Caffeine; Cholesterol; Dimyristoylphosphatidylcholine; Gallic Acid; Humans; Lipid | 2019 |
Chronic caffeine treatment reverses memory impairment and the expression of brain BNDF and TrkB in the PS1/APP double transgenic mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Behavior, Animal; Brain-Derived Neurotro | 2013 |
Beneficial effects of caffeine in a transgenic model of Alzheimer's disease-like tau pathology.
Topics: Alzheimer Disease; Animals; Caffeine; Disease Models, Animal; Hippocampus; Male; Memory Disorders; M | 2014 |
Protective effect of chronic caffeine intake on gene expression of brain derived neurotrophic factor signaling and the immunoreactivity of glial fibrillary acidic protein and Ki-67 in Alzheimer's disease.
Topics: Aluminum Chloride; Aluminum Compounds; Alzheimer Disease; Animals; Brain-Derived Neurotrophic Factor | 2015 |
Does Caffeine Consumption Modify Cerebrospinal Fluid Amyloid-β Levels in Patients with Alzheimer's Disease?
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Caffeine; Diet; Enzym | 2015 |
Quercetin, not caffeine, is a major neuroprotective component in coffee.
Topics: Alzheimer Disease; Astrocytes; Caffeine; Cells, Cultured; Chlorogenic Acid; Coffee; DNA Damage; Flav | 2016 |
Action of Caffeine as an Amyloid Inhibitor in the Aggregation of Aβ16-22 Peptides.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Caffeine; Hydrophobic and Hydrophilic Interaction | 2016 |
Tau hyperphosphorylation in the brain of ob/ob mice is due to hypothermia: Importance of thermoregulation in linking diabetes and Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Body Temperature; Body Temperature Regulation; Caffeine; Central Nervous | 2017 |
Coffee "breaks" Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Caffeine; Central Nervous System Stimulants; Coff | 2009 |
Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brai | 2009 |
Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer's disease transgenic mice.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of V | 2009 |
[Coffee and mental health].
Topics: Alzheimer Disease; Caffeine; Coffee; Humans; Mental Health; Parkinson Disease | 2009 |
Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway.
Topics: Adenosine A2 Receptor Antagonists; Alzheimer Disease; Amyloid beta-Peptides; Animals; Caffeine; Cell | 2009 |
Caffeine as a protective factor in dementia and Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Caffeine; Cardiovascular Diseases; Central Nervous System Stimulants; Coffe | 2010 |
Therapeutic opportunities for caffeine in Alzheimer's disease and other neurodegenerative disorders.
Topics: Alzheimer Disease; Caffeine; Humans; Neurodegenerative Diseases; Phosphodiesterase Inhibitors | 2010 |
Putative neuroprotective effects of caffeine in clinical trials. Concluding remarks.
Topics: Alzheimer Disease; Caffeine; Clinical Trials as Topic; Humans; Neuroprotective Agents | 2010 |
Caffeine protects against oxidative stress and Alzheimer's disease-like pathology in rabbit hippocampus induced by cholesterol-enriched diet.
Topics: Alzheimer Disease; Amyloid; Animals; Caffeine; Cholesterol, Dietary; Cytoprotection; Disease Models, | 2010 |
NMDA-mediated Ca(2+) influx drives aberrant ryanodine receptor activation in dendrites of young Alzheimer's disease mice.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cadmium Chloride; Caffeine; Central Nerv | 2010 |
Coffee intake in midlife and risk of dementia and its neuropathologic correlates.
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Asian; Brain; Caffeine; Case-Control Studie | 2011 |
Caffeine synergizes with another coffee component to increase plasma GCSF: linkage to cognitive benefits in Alzheimer's mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of Variance; Anim | 2011 |
Up-regulation of P-glycoprotein reduces intracellular accumulation of beta amyloid: investigation of P-glycoprotein as a novel therapeutic target for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; ATP Binding Cassette Transporter, Subfamily B, Member 1; C | 2011 |
Caffeine induces beneficial changes in PKA signaling and JNK and ERK activities in the striatum and cortex of Alzheimer's transgenic mice.
Topics: Alzheimer Disease; Animals; Blotting, Western; Brain; Caffeine; Central Nervous System Stimulants; C | 2011 |
High Blood caffeine levels in MCI linked to lack of progression to dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Caffeine; Case-Control Studies; Cognition; Cognitive Dys | 2012 |
Coffee and health. The latest buzz.
Topics: Alzheimer Disease; Blood Pressure; Bone and Bones; Caffeine; Central Nervous System Stimulants; Coff | 2012 |
Ryanodine receptor blockade reduces amyloid-β load and memory impairments in Tg2576 mouse model of Alzheimer disease.
Topics: Alzheimer Disease; Aminophenols; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Prec | 2012 |
Crude caffeine reduces memory impairment and amyloid β(1-42) levels in an Alzheimer's mouse model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Caffeine; Caspase 3; Coffea; Disease Models, Anim | 2012 |
Caffeine increases mitochondrial function and blocks melatonin signaling to mitochondria in Alzheimer's mice and cells.
Topics: Adenosine Triphosphate; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Antioxidants; Ca | 2012 |
[Coffee can protect against disease].
Topics: Alzheimer Disease; Anxiety; Caffeine; Cardiovascular Diseases; Coffee; Cognition; Diabetes Mellitus, | 2012 |
Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity.
Topics: Adenosine A2 Receptor Antagonists; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Caffein | 2003 |
The quest for a smart pill.
Topics: Alzheimer Disease; Animals; Behavior, Animal; Benzhydryl Compounds; Caffeine; Central Nervous System | 2003 |
Caffeine as a neuroprotective adenosine receptor antagonist.
Topics: Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Alzheimer Disease; Animals; Ca | 2004 |
Enhanced caffeine-induced Ca2+ release in the 3xTg-AD mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Brain; Caffeine; Calcium; Calcium Signaling; Calcium-Binding Proteins; C | 2005 |
Beta-amyloid treatment sensitizes mice to amphetamine-induced locomotion but reduces response to caffeine.
Topics: Adenosine; Adrenergic Agents; Alzheimer Disease; Amphetamine; Amyloid beta-Peptides; Animals; Avoida | 2004 |
Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production.
Topics: Adenosine; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; | 2006 |
Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice.
Topics: Adenosine A2 Receptor Antagonists; Alzheimer Disease; Amnesia; Amyloid beta-Peptides; Animals; Avoid | 2007 |
Use of artificial neural networks to determine cognitive impairment and therapeutic effectiveness in Alzheimer's transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Caffeine; Central Nervous System Stimula | 2008 |
Beta-amyloid enhances intracellular calcium rises mediated by repeated activation of intracellular calcium stores and nicotinic receptors in acutely dissociated rat basal forebrain neurons.
Topics: Acetylcholine; Action Potentials; Alzheimer Disease; Amyloid beta-Peptides; Animals; Basal Nucleus o | 2006 |
Caffeine blocks disruption of blood brain barrier in a rabbit model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Astrocytes; Blood-Brain Barrier; Caffeine; Central Nervous System Stimul | 2008 |
[Drug treatment of cerebral disorders in senility].
Topics: Aged; Alzheimer Disease; Amphetamines; Biotransformation; Caffeine; Dementia; Humans; Middle Aged; V | 1982 |
Fluorescent light-induced chromatid breaks distinguish Alzheimer disease cells from normal cells in tissue culture.
Topics: Alzheimer Disease; Caffeine; Case-Control Studies; Cells, Cultured; Chromatids; Cytarabine; DNA; DNA | 1996 |
Does caffeine intake protect from Alzheimer's disease?
Topics: Aged; Alzheimer Disease; Caffeine; Case-Control Studies; Central Nervous System Stimulants; Female; | 2002 |
Studies on choline transport enhancement into fibroblasts from normals and Alzheimer's donors.
Topics: Aged; Alzheimer Disease; Biological Transport; Caffeine; Cell Line; Cells, Cultured; Choline; Dexame | 1991 |